Search

Displaying results 7551 - 7560 of 10000 in total
  1. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. … TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.

  2. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. … AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  3. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

    Synonyms: 1H-PYRAZOLO(3,4-B)PYRIDINE-5-CARBOXYLIC ACID, 1-ETHYL-4-((1-METHYLETHYLIDENE)HYDRAZINO)-, ETHYL ESTERCategories: Heterocyclic Compounds, 1-Ring
  4. Drug

    ABX-PTH

    go.drugbank.com/drugs/DB05883
    Experimental

    ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform. … This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.

  5. Drug

    HCV-086

    go.drugbank.com/drugs/DB05884
    Experimental

    HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.

  6. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and … MAD) Phase I trials.

  7. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models … It is developed by Insmed and is currently under phase I of the clinical trial.

    Synonyms: rhIGFBP-3
  8. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. … The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

  9. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.

    Categories: Heterocyclic Compounds, 1-Ring
  10. Drug

    Resatorvid

    go.drugbank.com/drugs/DB05943
    Investigational

    Resatorvid is an investigational compound designed for the treatment of severe sepsis.